Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 29, 2025

Peter Schiff says 'biggest victims of inflation' will be ‘killed’ if they hold this investment. How to prepare for 2026

View original at finance.yahoo.com
Peter Schiff says 'biggest victims of inflation' will be ‘killed’ if they hold this investment. How to prepare for 2026 Gage Skidmore / Wikimedia Commons Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Morgan Stanley's suggested 20% allocation to gold is not chump change and could mark the start of a major shift as a huge wave of Wall Street money flows out of bonds and into gold

    80% confidence
  • Gold is now the anti-fragile asset to own, rather than Treasuries. High-quality equities and gold are the best hedges.

    80% confidence
  • Expects strong ETF inflows and continued central bank buying of gold

    80% confidence
  • Stocks can also be viewed as an inflation hedge, although not all stocks are the same in that respect

    80% confidence
  • The traditional 60/40 portfolio formula no longer holds up due to inflation

    80% confidence
  • Bonds are clearly the biggest victims of inflation. If you own bonds, inflation kills you. There is no hedge.

    80% confidence
  • For most people, the best thing to do is own the S&P 500 index fund

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Peter Schiff says 'biggest victims of inflation' will be ‘killed’ if they hold this investment. How to prepare for 2026 — Source | Via News | Finance Via News